Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 13, 2026, NDA 212640 (Exservan), held by Aquestive, was first approved by FDA on Nov 22, 2019, with 1 approved supplement and 0 published complete response letters.
First approved: Nov 22, 2019
Review: Standard
Supplements approved: 1
Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first; all 2 submissions below
Date
Submission
Status
Documents
Nov 22, 2019
Original applicationNew dosage form · Standard review
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
